Stivax – Effective for Chronic Pain

Stivax is a non-drug, minimally invasive treatment that has proven highly effective in chronic pain in many areas, peripheral arterial disease, neuropathies and other painful conditions as listed below – even when other pain management treatments have failed.   

  Peripheral Vascular Disease
●  Neuropathy
●  Post-amputation Pain
●  Herpetic Neuralgia
●  Trigeminal Neuralgia
●  Reflex Sympathetic Dystrophy (RSD)
●  Peripheral Artery Disease (PAD)
●  Migraines

●  Occipital Neuralgia
●  Back and Neck Pain
●  Post-Surgical Pain
●  Complex Regional Pain Syndrome (CRPS)
●  Diabetic Peripheral Neuropathy
●  Lateral Femoral Cutaneous Neuropathy
●  Traumatic Nerve Injuries

Patients temporarily wear a small, disposable neurostimulator device just below the ear for 3-4 successive two week periods, with one week off in between cycles (60 days total program). The device emits a low, imperceptible electrical current into the ear lobe, then on to the vagus nerve in the brain stem. This nerve affects the pain pathways in the spinal cord, and reduces pain signals regardless of their cause.  

Patients may report a 50% reduction in pain within the first few days, and 85% reduction in pain after the entire 60-day program. The sustained effect is usually long-term.  Some patients that have previously been relying on narcotic drug treatments have been able to discontinue the use of these conventional medicines.

PHYSICIAN USE ONLY

Only licensed medical providers may apply this device. Each treatment begins with a physician consultation and evaluation of suitability. Typically a minimum of 3-4 rounds of treatment using 3-4 single devices is recommended.

The device connects to the two tiny electrodes via a single lead wire.  The physician will percutaneously implant the 38-gauge electrodes in the triangular fossa of the ear lobe, and affix them with surgical grade adhesive tape.  The device will then be connected to the electrodes by the single lead wire, which will be affixed to a secure point on a location adjacent to the lower shoulder area.

The Stivax device emits a low, imperceptible electrical current into the ear lobe, then on to the vagus nerve in the brain stem. This nerve affects the pain pathways in the spinal cord and reduces pain signals regardless of their cause. Patients may report a 50% reduction in pain within the first few days, and 85% reduction in pain after the entire 60-day program. The sustained effect is usually long-term. Some patients that have previously been relying on narcotic drug treatments have been able to discontinue the use of these conventional medicines.

The single Stivax package contains a single device that is used throughout the entire 14-day treatment. Common packaging bundles 3 devices together with adjunctive components to cover a 60 day treatment period.

Neurostimulation is an established form of pain therapy that treats nerves with electrical stimulation rather than drugs.  While chronic pain is becoming better recognized by the medical community at large, the danger of opioids for addiction, diversion or misuse in patients is well documented. Opioid use is usually a poor choice for long-term, chronic conditions because it requires escalating doses to bring relief, and it carries with it a host of undesirable side effects.

Clinical studies show neurostimulation to be safe and effective, and is approved by the FDA to treat chronic pain of the trunk and limbs. Neurostimulation therapies modulate the function of nerves with low-intensity electrical impulses. Hypersensitive or damaged nerves that send unwarranted pain signals can be muted (or, in a sense, blocked) by neurostimulator impulses.

For more info, please visit our Neurostimulation Science Library.   >>

To become a provider, please register for access to physician product information, as well as the ability to purchase, choose shipping, payment method and receive your UPS tracking number online.  >>


NEXMED CARE LLC is the exclusive U.S. distributor for the Stivax device. License granted by Solace Advancement (USA) on behalf of Beigler GmbH, Mauerbach Austria.

INDICATIONS FOR USE: EUROPE (CE-MARK)
Complementary therapy to increase the transcutaneous oxygen partial pressure. Treatment to reduce the intensity of acute pain.

INDICATIONS FOR USE: U.S. (FDA)
Electro-acupuncture device for use in the practice of acupuncture by qualified practitioners of acupuncture as determined by the states.

SOURCES:  Biegler GmbH, Allhangstrasse 18a, 3001 Mauerbach, Austria,   Solace Advancement, 26711 Woodward Ave, #211, Huntington Woods, MI 48070

DISCLAIMER:  Providers should consult their own billing and reimbursement sources for appropriate billing codes and current rates applicable to them. It is our understanding that Medicare and some commercial insurance companies are not covering electro-acupuncture or auricular vagus nerve stimulation devices such as Stivax at this time.